GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test
GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests.
Providence will initially deploy Galleri at its California, Washington, and Oregon points of care, and the test could eventually be available across Providence’s entire seven-state footprint that includes more than 50 hospitals and nearly 1,100 health clinics serving 5 million patients. Providence’s aim is to pursue effective ways to identify cancer earlier in patients’ lives, and the health system will integrate the Galleri test into clinical care to help drive earlier detection of multiple cancers and try to improve and save lives.
“Today, the majority of cancers are found too late when outcomes are often fatal, and as a result, cancer is projected to become the leading cause of death worldwide,” said GRAIL CEO Hans Bishop. “Providence is a leading health system that shares our commitment to improving and saving lives, and our partnership moves us that much closer to making a tremendous and potentially life-altering difference for patients and providers. We are encouraged by interest in Galleri from health systems, medical practices, and self-insured employers, and excited by the progress in our mission to detect cancer early.”
“At Providence, we continuously strive to deliver the most innovating medical advances to our patients, and we are thrilled to partner with GRAIL on implementation research that may bring Galleri to all the communities we serve,” said Providence Chief Clinical Officer Amy Compton-Phillips, MD. “When combined with the power of our genomics research, having a single blood test that can detect more than 50 cancers advances our goal of finding cancer early, enabling our providers to administer treatment when it’s most likely to be successful and giving our patients the opportunity to achieve the best possible outcomes.”
GRAIL previously announced it expects to introduce Galleri in the second quarter of 2021. The blood test, which will be available by prescription only, will be available initially through partner health systems, medical practices, and self-insured employers.
Read the original press release here.